Semaglutide and Obesity: Real-World Clinical Applications and Outcomes

Authors

  • Swati Sucharita Dash Real-World Evidence & Health Economics and Outcome Research, Molecular Connections Analytics Pvt. Ltd., Heritage Building, B - Block, #59/2, Kaderanahalli, Outer Ring Rd, Banashankari Stage II, Bengaluru, Karnataka 560070
  • Merlin Roshma Sherin Real-World Evidence & Health Economics and Outcome Research, Molecular Connections Analytics Pvt. Ltd., Heritage Building, B - Block, #59/2, Kaderanahalli, Outer Ring Rd, Banashankari Stage II, Bengaluru, Karnataka 560070
  • Debalina Das Real-World Evidence & Health Economics and Outcome Research, Molecular Connections Analytics Pvt. Ltd., Heritage Building, B - Block, #59/2, Kaderanahalli, Outer Ring Rd, Banashankari Stage II, Bengaluru, Karnataka 560070
  • Guruprasad KS Rao Real-World Evidence & Health Economics and Outcome Research, Molecular Connections Analytics Pvt. Ltd., Heritage Building, B - Block, #59/2, Kaderanahalli, Outer Ring Rd, Banashankari Stage II, Bengaluru, Karnataka 560070

Keywords:

Obesity, Weight loss, Semaglutide, Real-world, GLP-1RA

Abstract

Obesity, a chronic and complex disease, is projected to have a prevalence of 49% by 2030 and is linked to various comorbidities, including type 2 diabetes, hypertension, dyslipidemia, stroke, coronary heart disease, and cancers, resulting in a substantial economic burden. Effective weight management is crucial to reduce morbidity and mortality. Semaglutide, initially developed as a GLP-1 receptor agonist for treating type 2 diabetes, is now being explored for its potential in addressing obesity. Its utilization is expanding to chronic weight management as it mimics the effects of GLP-1, regulating blood sugar levels and appetite. The FDA approved the use of a 2.4 mg injection of semaglutide once weekly for chronic weight management. Semaglutide proves efficacy for weight loss in obesity, endorsed by STEP trial findings and real-world data, with safety akin to GLP-1RA class, promoting long-term adherence. Its notable effects on albuminuria, HbA1c, heart failure, and quality of life herald a transformative paradigm in obesity and associated comorbidity management. Through a review of existing literature and clinical studies, this article provides a nuanced overview of the diverse real-world scenarios where semaglutide has been applied, elucidating its impact on weight management and associated health outcomes.

 

References

World Health Organization, “Obesity and overweight,” World Health Organization, Mar. 01, 2024.

“Obesity causes and treatments,” www.nhsinform.scot, Nov. 21, 2023.

S. Abdi Beshir et al., “A narrative review of approved and emerging anti-obesity medications,” Saudi Pharmaceutical Journal, vol. 31, no. 10, 101757, Oct. 2023, doi: https://doi.org/10.1016/j.jsps.2023.101757.

A. Ruban, K. Stoenchev, H. Ashrafian, and J. Teare, “Current treatments for obesity,” Clinical Medicine, vol. 19, no. 3, pp. 205–212, May 2019, doi: https://doi.org/10.7861/clinmedicine.19-3-205.

P. Marzullo et al., “Real-world evaluation of weekly subcutaneous treatment with semaglutide in a cohort of Italian diabetic patients,” Journal of Endocrinological Investigation, vol. 45, no. 8, pp. 1587–1598, Apr. 2022, doi: https://doi.org/10.1007/s40618-022-01799-2.

W. Ghusn et al., “Weight Loss Outcomes Associated With Semaglutide Treatment for Patients With Overweight or Obesity,” JAMA Network Open, vol. 5, no. 9, p. e2231982, Sep. 2022, doi: https://doi.org/10.1001/jamanetworkopen.2022.31982.

J. Xiang et al., “Clinical effectiveness of semaglutide on weight loss, body composition, and muscle strength in Chinese adults.,” PubMed, vol. 27, no. 20, pp. 9908–9915, Oct. 2023, doi: https://doi.org/10.26355/eurrev_202310_34169.

D. H. Ryan and S. R. Yockey, “Weight Loss and Improvement in Comorbidity: Differences at 5%, 10%, 15%, and Over,” Current Obesity Reports, vol. 6, no. 2, pp. 187–194, Apr. 2017, doi: https://doi.org/10.1007/s13679-017-0262-y.

K. Alabduljabbar, M. Alsaqaaby, K. J. Neff, M. Crotty, and C. W. le Roux, “Weight loss response in patients with obesity treated with injectable semaglutide in a real-world setting,” Endocrine, vol. 83, no. 2, pp. 392–398, Sep. 2023, doi: https://doi.org/10.1007/s12020-023-03534-0.

M. Menzen, T. L. Berentzen, A.-M. Catarig, S. Pieperhoff, J. Simon, and S. Jacob, “Real-World Use of Once-Weekly Semaglutide in Type 2 Diabetes: Results from SemaglUtide Real-world Evidence (SURE) Germany,” Experimental and Clinical Endocrinology & Diabetes, vol. 131, no. 4, pp. 205–215, Jan. 2023, doi: https://doi.org/10.1055/a-2007-2061.

W. C. Powell et al., “Medications and conditions associated with weight loss in patients prescribed semaglutide based on real?world data,” Obesity, vol. 31, no. 10, pp. 2482–2492, Aug. 2023, doi: https://doi.org/10.1002/oby.23859.

J. Bonnet et al., “Semaglutide 2.4 mg/wk for weight loss in patients with severe obesity and with or without a history of bariatric surgery,” Obesity, vol. 32, no. 1, pp. 50–58, Nov. 2023, doi: https://doi.org/10.1002/oby.23922.

Natia Murvelashvili et al., “Effectiveness of semaglutide versus liraglutide for treating post?metabolic and bariatric surgery weight recurrence,” Obesity, vol. 31, no. 5, pp. 1280–1289, Mar. 2023, doi: https://doi.org/10.1002/oby.23736.

A. B. Jensen et al., “Efficacy of the Glucagon-Like Peptide-1 Receptor Agonists Liraglutide and Semaglutide for the Treatment of Weight Regain After Bariatric Surgery: a Retrospective Observational Study,” Obesity Surgery, vol. 33, no. 4, pp. 1017–1025, Feb. 2023, doi: https://doi.org/10.1007/s11695-023-06484-8.

A. Lautenbach et al., “The Potential of Semaglutide Once-Weekly in Patients Without Type 2 Diabetes with Weight Regain or Insufficient Weight Loss After Bariatric Surgery—a Retrospective Analysis,” Obesity Surgery, vol. 32, no. 10, pp. 3280–3288, Jul. 2022, doi: https://doi.org/10.1007/s11695-022-06211-9.

S. Roy Chaudhuri, A. Majumder, P. Mukherjee, D. Sanyal, S. Chakraborty, and S. Chuyan, “Glycemic Control and the Weight Benefit of a Daily 7 mg Dose of Oral Semaglutide Versus an Alternate-Day 14 mg Dose of Oral Semaglutide From an Ambulatory Glucose Monitoring Data: A Retrospective Cohort Study From Eastern India,” Cureus, vol. 15, no. 6, p. e40179, Jun. 2023, doi: https://doi.org/10.7759/cureus.40179.

J. Seijas-Amigo et al., “Differences in weight loss and safety between the glucagon-like peptide-1 receptor agonists: A non-randomized multicenter study from the titration phase,” Primary Care Diabetes, vol. 17, no. 4, pp. 366–372, May 2023, doi: https://doi.org/10.1016/j.pcd.2023.05.004.

C. Di Loreto, V. Minarelli, G. Nasini, R. Norgiolini, and P. Del Sindaco, “Correction to: Effectiveness in Real World of Once-Weekly Semaglutide in People with Type 2 Diabetes: Glucagon-Like Peptide Receptor Agonist Naïve or Switchers from Other Glucagon-Like Peptide Receptor Agonists: Results from a Retrospective Observational Study in Umbria,” Diabetes Therapy, vol. 13, no. 6, p. 1251, Apr. 2022, doi: https://doi.org/10.1007/s13300-022-01263-7.

A. Okamoto, H. Yokokawa, T. Nagamine, H. Fukuda, T. Hisaoka, and T. Naito, “Efficacy and safety of semaglutide in glycemic control, body weight management, lipid profiles and other biomarkers among obese type 2 diabetes patients initiated or switched to semaglutide from other GLP-1 receptor agonists,” Journal of Diabetes & Metabolic Disorders, vol. 20, no. 2, pp. 2121–2128, Sep. 2021, doi: https://doi.org/10.1007/s40200-021-00899-9.

B. Aviles Bueno, M. J. Soler, L. Perez-Belmonte, A. Jimenez Millan, F. Rivas Ruiz, and M. D. Garcia de Lucas, “Semaglutide in type 2 diabetes with chronic kidney disease at high-risk progression—real-world clinical practice,” Clinical Kidney Journal, vol. 15, no. 8, pp. 1593–1600, Apr. 2022, doi: https://doi.org/10.1093/ckj/sfac096.

L. M. Pérez-Belmonte et al., “Efficacy and Safety of Semaglutide for the Management of Obese Patients With Type 2 Diabetes and Chronic Heart Failure in Real-World Clinical Practice,” Frontiers in Endocrinology, vol. 13, p. 851035, 2022, doi: https://doi.org/10.3389/fendo.2022.851035.

S. Ali et al., “Glucagon-like peptide-1 analogues in monogenic syndromic obesity: Real-world data from a large cohort of Alström syndrome patients,” Diabetes, Obesity & Metabolism, vol. 26, no. 3, pp. 989–996, Dec. 2023, doi: https://doi.org/10.1111/dom.15398.

S. O. Oguche, M. S. Maleshesh, D. Ishaq, "The Role of Epigenetics in the Development of Human Obesity and Type 2 Diabetes: A Review," International Journal of Medical Science Research and Practice, Vol.10, Issue.3, pp.6-15, 2023.

T. Parvin, T. Nasrin, J. Khatun, M. Chatterjee, "Predictive Machine Learning Model for Detection and Classification of Diabetes", International Journal of Scientific Research in Multidisciplinary Studies , Vol.7, Issue.9, pp.11-17, 2021.

H. Gasoyan, M. A. Fiala, M. Doering, R. Vij, M. Halpern, and G. A. Colditz, “Disparities in Multiple Myeloma Treatment Patterns in the United States: A Systematic Review,” Clinical Lymphoma, Myeloma & Leukemia, vol. 23, no. 11, pp. e420–e427, Nov. 2023, doi: https://doi.org/10.1016/j.clml.2023.08.008.

Downloads

Published

2024-03-31

How to Cite

Dash, S. S., Sherin, M. R., Das, D., & Rao, G. K. (2024). Semaglutide and Obesity: Real-World Clinical Applications and Outcomes. International Journal of Medical Science Research and Practice, 11(1), 1–14. Retrieved from https://ijmsrp.isroset.org/index.php/j/article/view/71

Issue

Vol. 11 No. 1 (2024): Volume-11, Issue-1 March 2024

Section

Research Article

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors contributing to this journal agree to publish their articles under the Creative Commons Attribution 4.0 International License, allowing third parties to share their work (copy, distribute, transmit) and to adapt it, under the condition that the authors are given credit and that in the event of reuse or distribution, the terms of this license are made clear.